[The value and possibilities of immunotherapy in the treatment of allergic rhinitis]

Abstract

Aside from allergen avoidance and medication, specific immunotherapy, represents the third important mainstay in a balanced therapeutic concept for the treatment of allergic rhinitis. In the case of subcutaneous immunotherapy (SCIT), clinical effectiveness, duration of the therapeutic result, prevention of bronchial asthma, reduced generation of additional co-sensitizations, and tolerability are all well-established. For such modern therapeutic concepts as "cluster", "rush" and ultra-rush" regimens, this is not yet the case. For sublingual therapy, too, questions about the impact on asthma development, new sensitizations and long-term outcomes have not yet been fully clarified.